Orthopedic startup Insight Surgery is now more financially sound, having completed a $2.5 million Series A equity investment led by Nodenza Venture Partners.

The investment follows U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s surgical guides for orthopedic and orthopedic-oncology procedures, and will be used to further accelerate its U.S. market growth. Insight Surgery’s planned expansion will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk, and expedite recovery.

“Our mission is to make advanced surgical planning tools accessible and scalable across the U.S. healthcare system. This investment allows us to accelerate our plan to enable every orthopedic surgeon in the U.S. to have easy access to personalized surgical devices within surgically meaningful timelines,” Insight Surgery CEO Henry Pinchbeck said. “We’re excited to build on the momentum we’ve already seen with leading clinicians. We’re not just focused on improving surgical precision—we’re focused on doing it in a way that makes financial sense for healthcare systems. By reducing operating time, streamlining workflows, and lowering complication and readmission rates, our technology can help hospitals drive down costs while delivering better care. This investment allows us to scale that impact nationwide.”

EmbedMed—Insight Surgery’s proprietary platform—digitizes the surgical planning process and enables companies to rapidly design and manufacture patient-specific orthopedic surgical guides.

EmbedMed processes patient scan data and is a pre-operative software tool for simulating and evaluating surgical planning options. The output files from the system can be provided digitally, or as physical models and surgical guides. The platform’s advanced nature enables surgical guides to be provided to surgeons in 10 working days from Insight’s ISO 13485-certified and FDA-registered facilities in the United States.

“Insight’s technology makes it possible for me and my colleagues to operate with greater precision and speed, which directly improves outcomes for patients and reduces the likelihood of costly complications,” musculoskeletal oncology surgeon Dr. Adam Levin stated. “For hospitals and providers, this means fewer revisions, shorter operative times, and faster recoveries. It’s a rare example of a surgical innovation that’s both clinically and economically compelling.”

Insight Surgery recently launched its U.S. business by opening a cleanroom manufacturing facility at the Texas Medical Centre (TMC) in Houston. The company has since gained considerable market traction, entering into a strategic partnership with Ricoh USA and partnering with surgeons at several major U.S. hospitals, including the Hospital for Special Surgery in New York, University Hospitals of Chicago, University of Florida Health, and UAB in Birmingham, Ala.  

The Series A raise, and Nodenza’s support, will unlock U.S. expansion opportunities for Insight Surgery, enabling the firm to open two new manufacturing facilities at East and West Coast hospital sites. The company has plans to double its U.S. headcount in the coming months.  

“Insight Surgery is exactly the kind of company we look to back. Disruptive tech, with clear benefits to patients being delivered now not tomorrow, and—with the right funding in place—the potential to be the leader in the personalized surgery market,” Nodenza Managing Partner Ross Morton commented. “Their platform addresses a real need in orthopedic surgery by enabling better outcomes via bespoke products, which resonates with both surgeons and health systems looking to meet patient demand in personalized surgery. We believe Insight, with the support that the Nodenza team can provide, is well-positioned to scale rapidly across the U.S.”

Founded in the U.K., and launched in the United States in 2023, Insight Surgery specializes in personalized surgical planning and guide production for orthopedic, orthopedic oncology, and maxillofacial surgeries. With FDA clearances and a commitment to innovation, Insight Surgery delivers precision surgical solutions that improve patient outcomes and operational efficiency in healthcare settings.

A New York-based Life Sciences Venture Fund, Nodenza Venture Partners provides financial and operational support to biotech and medtech companies. Established by a team of experienced life sciences entrepreneurs, founders and leaders, its approach leverages Nodenza’s extensive expertise in the creation and growth of new companies, as well as late-stage product development and launch. The firm invests in Seed through Series B companies that are either in development or beginning commercialization.